For much of medical history, physicians may have been able to recognize familial patterns in eye conditions but could offer little to change the course of disease. Thankfully, that is beginning to shift. Genetics is moving beyond identifying inherited risks toward treatments that address the biological instructions behind disease. 

Gene Augmentation

One approach is to deliver a working copy of a gene to cells that lack a functional version. The added copy helps cells produce missing proteins. Clinicians often use a modified virus to carry the genetic material into targeted eye tissues.

It may sound like science fiction, but it’s more than a laboratory concept. Luxturna, approved by the FDA in 2017, treats patients with a rare inherited retinal condition caused by variants in the RPE65 gene. It can improve functional vision, particularly in dim lighting; however, it requires enough surviving retinal cells to respond and does not restore normal sight or treat every inherited retinal disorder.

Gene Editing

Rather than supplying another gene copy, CRISPR is a groundbreaking technology that allows scientists to edit DNA at specific locations. In a clinical trial led by Mass Eye and Ear, researchers used CRISPR to treat a rare inherited retinal disorder. Eleven of the 14 participants improved on at least one measure of vision or quality of life. These findings are encouraging, but larger studies and longer follow-up are needed to establish safety and effectiveness.

Gene-Based Drug Production

The possibilities extend beyond rare inherited diseases. Researchers are investigating gene therapies for wet age-related macular degeneration that help eye cells manufacture therapeutic proteins. Rather than relying entirely on repeated medication injections to suppress abnormal blood vessel growth, the goal is to provide a sustained supply within the eye. Whether these treatments can safely provide lasting benefits and consistently reduce the need for injections remains under investigation.

Important obstacles remain. Treatments must reach the correct cells, deliver an appropriate dose, and avoid harmful inflammation or unintended effects. Correcting genetic instructions cannot replace cells already lost. Ultimately, their cost, accessibility, and duration of benefit will help determine how widely these treatments become available.

Key Takeaways

Even as genetic treatments become available for more eye diseases, regular comprehensive eye examinations remain essential. A thorough eye evaluation can identify changes before symptoms appear and help determine when specialized testing or referral is appropriate. The future may offer increasingly powerful ways to alter disease, but early detection and informed care remain essential to protecting vision.

Sponsored articles are submitted by our advertisers. The advertiser is solely responsible for the content of this article.